Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ENDPQ Endo International
0.096-0.001-1.03%
Close
02/04 09:30 ET
High
0.099
Open
0.093
Turnover
42.16K
Low
0.090
Pre Close
0.097
Volume
446.95K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Endo Cutting 90 Positions as It Will Stop Sales of Cellulite Treatment Qwo
Endo Non-GAAP EPS of $0.47, Revenue of $541.69M
Endo International Not Providing Guidance at This Time >ENDPQ
Endo International Not Providing Guidance at This Time >ENDPQ
Endo International 3Q Rev $541.7M >ENDPQ
Endo International 3Q Adj EPS 47c >ENDPQ
Endo International 3Q Loss/Shr $3.07 >ENDPQ
Endo International 3Q Loss/Shr $3.07 >ENDPQ
Press Release: ENDO REPORTS THIRD-QUARTER 2022 -5-
Three Months Ended September 30, 2021 -----------------------------------------------------------------------
Endo Presents New Qwo® (Collagenase Clostridium Histolyticum-aaes) Data at the American Society for Dermatologic Surgery's Annual Meeting
DUBLIN, Oct. 7, 2022 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that data from studies of Endo Aesthetics' Qwo® (collagenase clostridium histolyticum-aaes), an FDA-approved injectable for the treatment of moderate to severe cellulite in the buttocks of adult women, will be presented during the American Society for Dermatologic Surgery annual meeting, taking place now through October 10 in Denver, CO.
Venus Concept Taps Endo's Former CEO As New Chief Executive, Withdraws FY22 Guidance
Venus Concept Inc (NASDAQ:VERO) appointed Rajiv De Silva as the company's CEO and board member, effective October 2.
Endo Bankruptcy Judge Approves Rep for Future Opioid Victims
By Jonathan Randles A New York bankruptcy judge on Wednesday approved Endo International PLC's request to hire a fiduciary in its chapter 11 case to represent the interests of future opioid claimants
Company Overview
More
Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.
CEO： Mr. Blaise A. Coleman
Market： Pink Market
Listing Date： 07/18/2000
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet